Last Updated: July 22, 2026

ZILXI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zilxi patents expire, and what generic alternatives are available?

Zilxi is a drug marketed by Journey and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in ten countries.

The generic ingredient in ZILXI is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ZILXI?
  • What are the global sales for ZILXI?
  • What is Average Wholesale Price for ZILXI?
Pharmacology for ZILXI
Paragraph IV (Patent) Challenges for ZILXI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZILXI Topical Aerosol Foam minocycline hydrochloride 1.50% 213690 1 2022-02-28

US Patents and Regulatory Information for ZILXI

ZILXI is protected by nine US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZILXI

See the table below for patents covering ZILXI around the world.

Country Patent Number Title Estimated Expiration
Australia 2010302350 Surfactant-free water-free foamable compositions, breakable foams and gels and their uses ⤷  Start Trial
Australia 2015224534 SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES ⤷  Start Trial
Brazil 112012007473 composições tópicas de tetraciclina e respectivo método de uso ⤷  Start Trial
Canada 2776366 COMPOSITIONS MOUSSANTES SANS EAU ET SANS SURFACTANT, MOUSSES ET GELS FRIABLES, AINSI QUE LEURS UTILISATIONS (SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES) ⤷  Start Trial
Canada 2776471 COMPOSITIONS MOUSSANTES DEPOURVUES D'AGENT TENSIOACTIF ET D'EAU ET MOUSSES CASSABLES ET LEURS UTILISATIONS (SURFACTANT-FREE, WATER-FREE, FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES) ⤷  Start Trial
Canada 2776474 COMPOSITIONS DE TETRACYCLINE A USAGE TOPIQUE (TOPICAL TETRACYCLINE COMPOSITIONS) ⤷  Start Trial
Canada 2776482 COMPOSITIONS, GELS ET MOUSSES COMPRENANT DES MODULATEURS DE RHEOLOGIE ET LEURS UTILISATIONS (COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.